Abstract | BACKGROUND: OBJECTIVE: STUDY DESIGN: We obtained plasma samples before delivery from 16 participants with placenta accreta spectrum and 10 control subjects with similar gestational ages (35.1 vs 35.5 weeks gestation, respectively). We analyzed plasma samples with an aptamer-based proteomics platform for alterations in 1305 unique proteins. Heat maps of the most differentially expressed proteins (T test, P<.01) were generated with matrix visualization and analysis software. Principal component analysis was performed with the use of all 1305 proteins and the top 21 dysregulated proteins. We then confirmed dysregulated proteins using enzyme-linked immunosorbent assay and report significant differences between placenta accreta spectrum and control cases (Wilcoxon-rank sum test, P<.05). RESULTS: CONCLUSION:
|
Authors | Scott A Shainker, Robert M Silver, Anna M Modest, Michele R Hacker, Jonathan L Hecht, Saira Salahuddin, Simon T Dillon, Erin J Ciampa, Mary E D'Alton, Hasan H Otu, Alfred Z Abuhamad, Brett D Einerson, D Ware Branch, Blair J Wylie, Towia A Libermann, S Ananth Karumanchi |
Journal | American journal of obstetrics and gynecology
(Am J Obstet Gynecol)
Vol. 223
Issue 3
Pg. 433.e1-433.e14
(09 2020)
ISSN: 1097-6868 [Electronic] United States |
PMID | 32199927
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2020 Elsevier Inc. All rights reserved. |
Chemical References |
- Biomarkers
- Vascular Endothelial Growth Factors
|
Topics |
- Adult
- Biomarkers
(blood)
- Case-Control Studies
- Female
- Humans
- Placenta Accreta
(blood)
- Pregnancy
- Pregnancy Trimester, Third
- Prenatal Diagnosis
- Proteomics
- Vascular Endothelial Growth Factors
(blood)
|